Event sequence | WBC (×109) | Eosinophils in PB (%, AEC) | Eosinophils in BM (%) | Blasts in BM (%) | Diagnosis | Intervention | Disease status |
---|---|---|---|---|---|---|---|
Initial presentation | 44.6 | 1, 0.45 | 1 | 7 | CMML-1 | SGI-110 | Refractory |
After 2Â months | 65.1 | 9, 5.8 | 5 | 4 | CMML-1 | SGI-110 | Progression |
After 1 month | 126 | 11, 13.8 | 16 | 12 | Myelodysplastic/myeloproliferative neoplasm with eosinophilia, and PDGFRA rearrangement | Fludarabine + Cytarabine | Progression |
After 1 month | 6.4 | 1, 0.06 | 1 | 26 | AML with PDGFRA rearrangement | Imatinib (with Idarubicin + Cutarabine) | Remission |